IRAK-1 inhib 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 
29 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vonjo (pacritinib) / SOBI
CTI BioPharma_COVID-: CTI BioPharma Initiates Phase III Pacritinib Trial in COVID-19

Not yet recruiting
3
358
US
Enpaxiq (pacritinib) - Baxter Healthcare, CTI BioPharma
Baxter Healthcare, CTI BioPharma
Severe COVID-19
 
 
ACTRN12614000740695: Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia (PAC326)

Recruiting
3
300
 
Cell Therapeutics Inc., Cell Therapeutics Inc.
Primary Myelofibrosis
 
 
2013-004000-19: A study comparing current standard therapies with pacritinib taken by mouth for the treatment of myelofibrosis (either diagnosed alone or after polycythemia vera or essential thrombocytopenia) in patients with a low platelet count

Completed
3
300
Europe, RoW
pacritinib, SB1518, Capsule, hard
CTI BioPharma Corp., Cell Therapeutics, Inc., CTI BioPharma Corp., Cell Therapeutics, Inc.
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Thrombocytopenia, Myelofibrosis with a low platelet count, Diseases [C] - Cancer [C04]
 
 
2012-004239-21: A study comparing current standard therapies with pacritinib taken by mouth for the treatment of myelofibrosis (either diagnosed alone or after polycythemia vera or essential thrombocytopenia)

Completed
3
322
Europe, RoW
pacritinib, SB1518, Capsule, hard
CTI BioPharma Corp., CELL THERAPEUTICS INC., CTI BioPharma Corp., Cell Therapeutics Inc
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis, myelofibrosis, Diseases [C] - Cancer [C04]
 
 
2020-000111-69: PACIFICA Phase 3: A Study of Pacritinib Versus Physician’s Choice in Patients with Myelofibrosis

Ongoing
3
399
RoW, Europe
Pacritinib, Ruxolitinib, Hydroxyurea, methylprednisolone, Dexamethasone, Prednisone, [N/A], [Pacritinib], Capsule, hard, Tablet, Soluble tablet
CTI BioPharma Corp., Sobi Inc., CTI BIOPHARMA CORP., CTI BioPharma Corp., Sobi Inc.
Primary Myelofibrosis, Post-essential thrombocythemia myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL), Post polycythaemia vera myelofibrosis, Primary or Secondary Myelofibrosis (MF), Diseases [C] - Cardiovascular Diseases [C14]
 
 
PACIFICA, NCT03165734 / 2017-001772-28: A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Calendar May 2026 - Sep 2026: Data from PACIFICA trial for myelofibrosis
Recruiting
3
399
Europe, Canada, Japan, US, RoW
Pacritinib, Physician's Choice medications, corticosteroids, hydroxyurea, danazol, low-dose ruxolitinib
Swedish Orphan Biovitrum, PSI CRO
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
12/26
07/27
HOVON134MF, NCT03645824 / 2015-000195-98: Myelofibrosis Treated With Pacritinib Before aSCT.

Active, not recruiting
2
61
Europe
Pacritinib
Stichting Hemato-Oncologie voor Volwassenen Nederland, Dutch Cancer Society, CTI BioPharma
Myelofibrosis
07/23
02/27
NCT04282187: Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Recruiting
2
25
US
Decitabine, 127716, 2''-Deoxy-5-azacytidine, 5-Aza-2''-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Ruxolitinib, 941678-49-5, INCB-18424, Jakafi, Oral JAK Inhibitor INCB18424, Fedratinib, 936091-26-8, SAR302503, TG101348, Questionnaire Administration, Pacritinib, 937272-79-2, Oral JAK2 Inhibitor SB1518, SB 1518, SB-1518, SB1518
University of Washington
Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Primary Myelofibrosis, Secondary Myelofibrosis
11/26
11/26
NCT06782373: A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

Recruiting
2
78
Europe, Canada, Japan, US
Pacritinib, Placebo
Swedish Orphan Biovitrum, PSI CRO
VEXAS, VEXAS Syndrome
08/27
08/27
BLAST, NCT04635059: Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer

Terminated
2
6
US
Pacritinib, SB1518
Medical College of Wisconsin
Prostate Cancer
11/23
10/24
NCT06986174: A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

Not yet recruiting
2
30
US
Pacritinib, SB1518, VONJO, Pacritinib Citrate
Shayna Sarosiek, MD, Sobi, Inc.
Waldenström Macroglobulinemia, Lymphoplasmacytic Lymphoma, B-Cell Lymphoproliferative Disorder, Indolent Lymphoma
10/28
10/32
PROSPERA, NCT07033598: Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

Not yet recruiting
2
66
NA
Pacritinib, Hydroxyurea
Theradex, Sobi, Inc.
Leukemia, Myelomonocytic, Chronic
07/28
12/28
SENTRY-2, NCT05980806: A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Hourglass May 2025 - Jun 2025 : Preliminary data from 60 mg cohort for JAKi-naive MF with moderate thrombocytopenia
Recruiting
2
118
Europe, Canada, US, RoW
Selinexor 60 mg, KPT-330, Selinexor 40 mg, Ruxolitinib, JAKAFI, Pacritinib, VONJO, Momelotinib, OJJAARA
Karyopharm Therapeutics Inc
Myelofibrosis, Moderate Thrombocytopenia
04/26
10/28
NCT04858256: Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

Recruiting
2
100
US
Pacritinib
University of Michigan Rogel Cancer Center, National Institutes of Health (NIH), National Cancer Institute (NCI)
T-Cell Neoplasm, Lymphoproliferative Disorders
11/27
11/28
NCT06052618: Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)

Recruiting
2
75
US
Pacritinib
National Cancer Institute (NCI)
KSHV Inflammatory Cytokine Syndrome (KICS), Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
01/33
01/34
NCT02891603: A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

Completed
1/2
40
US
Pacritinib, PAC, tyrosine kinase inhibitor (TKI), Sirolimus, Rapamune, Tacrolimus, Prograf, Allogenic hematopoietic cell transplant (alloHCT)
H. Lee Moffitt Cancer Center and Research Institute, CTI BioPharma, National Heart, Lung, and Blood Institute (NHLBI)
Graft Vs Host Disease, GVHD
01/22
04/22
NCT04520269: A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)

Recruiting
1/2
74
RoW
Pacritinib
National University Hospital, Singapore
Breast Cancer
07/23
07/23
NCT05531786: Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Recruiting
1/2
50
US
Pacritinib
National Cancer Institute (NCI)
Graft vs Host Disease
07/25
07/25
NCT06159491: Pacritinib in CMML

Recruiting
1/2
26
US
Pacritinib, Azacitidine
Douglas Tremblay, Sobi, Inc.
Chronic Myelomonocytic Leukemia
07/25
05/27
NCT06516887: Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma

Recruiting
1/2
44
US
bemcentinib, pacritinib
The University of Texas Health Science Center at San Antonio, National Cancer Institute (NCI)
Advanced Lung Adenocarcinoma
09/27
09/27
NCT06303193: Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Not yet recruiting
1/2
160
US
pacritinib
National Cancer Institute (NCI)
Myelodysplastic Syndromes
01/30
01/35
NCT05657613: Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

Completed
1
60
US
CYP450 Cocktail and Transporter Substrates with Pacritinib, Vonjo, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
CTI BioPharma, PPD DEVELOPMENT, LP
Drug Interactions
06/23
06/23
NCT06218628: Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Recruiting
1
24
US
Talazoparib, talzenna, pacritinib, vonjo
Fox Chase Cancer Center
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Chronic Myelomonocytic Leukemia, Polycythemia Vera, Essential Thrombocytosis
08/29
08/30
NCT05552183: Study to Evaluate the Safety, Tolerability, and PK of Pacritinib

Completed
1
29
US
oral dose of 200 mg pacritinib twice daily (BID)
CTI BioPharma, PPD DEVELOPMENT, LP
Hepatic Impairment
06/24
06/24
NCT06538181: Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

Recruiting
1
15
US
Pacritinib
Washington University School of Medicine, Swedish Orphan Biovitrum
E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome, VEXAS, Vexas Syndrome
03/27
02/29
NCT06414681: Combination of Tagraxofusp with Pacritinib in Patients with Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy with the Approved JAK Inhibitors or in Which Therapy with the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

Not yet recruiting
1
20
NA
Tagraxofusp, Pacritinib
University of Kansas Medical Center
Myelofibrosis，MF
12/26
12/26
IMproveMF, NCT05371964: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

Checkmark Trial updates from IMPROVEMF trial in combination with ruxolitinib in 1L myelofibrosis
Dec 2022 - Dec 2022: Trial updates from IMPROVEMF trial in combination with ruxolitinib in 1L myelofibrosis
Recruiting
1
51
US
Imetelstat sodium, GRN163L, Ruxolitinib, Pacritinib, Momelotinib, Fedratinib
Geron Corporation
Myelofibrosis
02/27
08/28
NCT06675123: Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

Not yet recruiting
1
10
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, BTK Inhibitor, Tyrosine-Protein Kinase BTK Protein, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Pacritinib, Oral JAK2 Inhibitor SB1518, SB 1518, SB-1518, SB1518, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
11/26
11/26
R289 / Rigel
C-906289-002, NCT05308264: Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

Recruiting
1/2
86
US
R906289 Monosodium (R289 Na), R906289 Monosodium
Rigel Pharmaceuticals
Low Risk Myelodysplastic Syndromes
08/26
12/26
R191 / Rigel
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vonjo (pacritinib) / SOBI
CTI BioPharma_COVID-: CTI BioPharma Initiates Phase III Pacritinib Trial in COVID-19

Not yet recruiting
3
358
US
Enpaxiq (pacritinib) - Baxter Healthcare, CTI BioPharma
Baxter Healthcare, CTI BioPharma
Severe COVID-19
 
 
ACTRN12614000740695: Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia (PAC326)

Recruiting
3
300
 
Cell Therapeutics Inc., Cell Therapeutics Inc.
Primary Myelofibrosis
 
 
2013-004000-19: A study comparing current standard therapies with pacritinib taken by mouth for the treatment of myelofibrosis (either diagnosed alone or after polycythemia vera or essential thrombocytopenia) in patients with a low platelet count

Completed
3
300
Europe, RoW
pacritinib, SB1518, Capsule, hard
CTI BioPharma Corp., Cell Therapeutics, Inc., CTI BioPharma Corp., Cell Therapeutics, Inc.
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Thrombocytopenia, Myelofibrosis with a low platelet count, Diseases [C] - Cancer [C04]
 
 
2012-004239-21: A study comparing current standard therapies with pacritinib taken by mouth for the treatment of myelofibrosis (either diagnosed alone or after polycythemia vera or essential thrombocytopenia)

Completed
3
322
Europe, RoW
pacritinib, SB1518, Capsule, hard
CTI BioPharma Corp., CELL THERAPEUTICS INC., CTI BioPharma Corp., Cell Therapeutics Inc
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis, myelofibrosis, Diseases [C] - Cancer [C04]
 
 
2020-000111-69: PACIFICA Phase 3: A Study of Pacritinib Versus Physician’s Choice in Patients with Myelofibrosis

Ongoing
3
399
RoW, Europe
Pacritinib, Ruxolitinib, Hydroxyurea, methylprednisolone, Dexamethasone, Prednisone, [N/A], [Pacritinib], Capsule, hard, Tablet, Soluble tablet
CTI BioPharma Corp., Sobi Inc., CTI BIOPHARMA CORP., CTI BioPharma Corp., Sobi Inc.
Primary Myelofibrosis, Post-essential thrombocythemia myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL), Post polycythaemia vera myelofibrosis, Primary or Secondary Myelofibrosis (MF), Diseases [C] - Cardiovascular Diseases [C14]
 
 
PACIFICA, NCT03165734 / 2017-001772-28: A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Calendar May 2026 - Sep 2026: Data from PACIFICA trial for myelofibrosis
Recruiting
3
399
Europe, Canada, Japan, US, RoW
Pacritinib, Physician's Choice medications, corticosteroids, hydroxyurea, danazol, low-dose ruxolitinib
Swedish Orphan Biovitrum, PSI CRO
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
12/26
07/27
HOVON134MF, NCT03645824 / 2015-000195-98: Myelofibrosis Treated With Pacritinib Before aSCT.

Active, not recruiting
2
61
Europe
Pacritinib
Stichting Hemato-Oncologie voor Volwassenen Nederland, Dutch Cancer Society, CTI BioPharma
Myelofibrosis
07/23
02/27
NCT04282187: Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Recruiting
2
25
US
Decitabine, 127716, 2''-Deoxy-5-azacytidine, 5-Aza-2''-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Ruxolitinib, 941678-49-5, INCB-18424, Jakafi, Oral JAK Inhibitor INCB18424, Fedratinib, 936091-26-8, SAR302503, TG101348, Questionnaire Administration, Pacritinib, 937272-79-2, Oral JAK2 Inhibitor SB1518, SB 1518, SB-1518, SB1518
University of Washington
Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Primary Myelofibrosis, Secondary Myelofibrosis
11/26
11/26
NCT06782373: A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

Recruiting
2
78
Europe, Canada, Japan, US
Pacritinib, Placebo
Swedish Orphan Biovitrum, PSI CRO
VEXAS, VEXAS Syndrome
08/27
08/27
BLAST, NCT04635059: Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer

Terminated
2
6
US
Pacritinib, SB1518
Medical College of Wisconsin
Prostate Cancer
11/23
10/24
NCT06986174: A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

Not yet recruiting
2
30
US
Pacritinib, SB1518, VONJO, Pacritinib Citrate
Shayna Sarosiek, MD, Sobi, Inc.
Waldenström Macroglobulinemia, Lymphoplasmacytic Lymphoma, B-Cell Lymphoproliferative Disorder, Indolent Lymphoma
10/28
10/32
PROSPERA, NCT07033598: Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

Not yet recruiting
2
66
NA
Pacritinib, Hydroxyurea
Theradex, Sobi, Inc.
Leukemia, Myelomonocytic, Chronic
07/28
12/28
SENTRY-2, NCT05980806: A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Hourglass May 2025 - Jun 2025 : Preliminary data from 60 mg cohort for JAKi-naive MF with moderate thrombocytopenia
Recruiting
2
118
Europe, Canada, US, RoW
Selinexor 60 mg, KPT-330, Selinexor 40 mg, Ruxolitinib, JAKAFI, Pacritinib, VONJO, Momelotinib, OJJAARA
Karyopharm Therapeutics Inc
Myelofibrosis, Moderate Thrombocytopenia
04/26
10/28
NCT04858256: Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

Recruiting
2
100
US
Pacritinib
University of Michigan Rogel Cancer Center, National Institutes of Health (NIH), National Cancer Institute (NCI)
T-Cell Neoplasm, Lymphoproliferative Disorders
11/27
11/28
NCT06052618: Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)

Recruiting
2
75
US
Pacritinib
National Cancer Institute (NCI)
KSHV Inflammatory Cytokine Syndrome (KICS), Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
01/33
01/34
NCT02891603: A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

Completed
1/2
40
US
Pacritinib, PAC, tyrosine kinase inhibitor (TKI), Sirolimus, Rapamune, Tacrolimus, Prograf, Allogenic hematopoietic cell transplant (alloHCT)
H. Lee Moffitt Cancer Center and Research Institute, CTI BioPharma, National Heart, Lung, and Blood Institute (NHLBI)
Graft Vs Host Disease, GVHD
01/22
04/22
NCT04520269: A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)

Recruiting
1/2
74
RoW
Pacritinib
National University Hospital, Singapore
Breast Cancer
07/23
07/23
NCT05531786: Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Recruiting
1/2
50
US
Pacritinib
National Cancer Institute (NCI)
Graft vs Host Disease
07/25
07/25
NCT06159491: Pacritinib in CMML

Recruiting
1/2
26
US
Pacritinib, Azacitidine
Douglas Tremblay, Sobi, Inc.
Chronic Myelomonocytic Leukemia
07/25
05/27
NCT06516887: Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma

Recruiting
1/2
44
US
bemcentinib, pacritinib
The University of Texas Health Science Center at San Antonio, National Cancer Institute (NCI)
Advanced Lung Adenocarcinoma
09/27
09/27
NCT06303193: Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Not yet recruiting
1/2
160
US
pacritinib
National Cancer Institute (NCI)
Myelodysplastic Syndromes
01/30
01/35
NCT05657613: Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

Completed
1
60
US
CYP450 Cocktail and Transporter Substrates with Pacritinib, Vonjo, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
CTI BioPharma, PPD DEVELOPMENT, LP
Drug Interactions
06/23
06/23
NCT06218628: Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Recruiting
1
24
US
Talazoparib, talzenna, pacritinib, vonjo
Fox Chase Cancer Center
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Chronic Myelomonocytic Leukemia, Polycythemia Vera, Essential Thrombocytosis
08/29
08/30
NCT05552183: Study to Evaluate the Safety, Tolerability, and PK of Pacritinib

Completed
1
29
US
oral dose of 200 mg pacritinib twice daily (BID)
CTI BioPharma, PPD DEVELOPMENT, LP
Hepatic Impairment
06/24
06/24
NCT06538181: Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

Recruiting
1
15
US
Pacritinib
Washington University School of Medicine, Swedish Orphan Biovitrum
E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome, VEXAS, Vexas Syndrome
03/27
02/29
NCT06414681: Combination of Tagraxofusp with Pacritinib in Patients with Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy with the Approved JAK Inhibitors or in Which Therapy with the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

Not yet recruiting
1
20
NA
Tagraxofusp, Pacritinib
University of Kansas Medical Center
Myelofibrosis，MF
12/26
12/26
IMproveMF, NCT05371964: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

Checkmark Trial updates from IMPROVEMF trial in combination with ruxolitinib in 1L myelofibrosis
Dec 2022 - Dec 2022: Trial updates from IMPROVEMF trial in combination with ruxolitinib in 1L myelofibrosis
Recruiting
1
51
US
Imetelstat sodium, GRN163L, Ruxolitinib, Pacritinib, Momelotinib, Fedratinib
Geron Corporation
Myelofibrosis
02/27
08/28
NCT06675123: Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

Not yet recruiting
1
10
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, BTK Inhibitor, Tyrosine-Protein Kinase BTK Protein, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Pacritinib, Oral JAK2 Inhibitor SB1518, SB 1518, SB-1518, SB1518, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
11/26
11/26
R289 / Rigel
C-906289-002, NCT05308264: Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

Recruiting
1/2
86
US
R906289 Monosodium (R289 Na), R906289 Monosodium
Rigel Pharmaceuticals
Low Risk Myelodysplastic Syndromes
08/26
12/26
R191 / Rigel
No trials found

Download Options